ABSTRACT The electrophysiologic effects of intravenous lorcainide (2.2 mg/kg) in 10 patients were compared with the electrophysiologic effects of oral lorcainide (mean dose 400 mg/day for 8 days) in 11 patients, all with recurrent ventricular tachycardia that could be induced with programmed stimulation. Intravenous and oral lorcainide resulted in similar prolongation of the QRS, QT, and HV intervals, but only oral lorcainide resulted in prolongation of the AH interval and atrial and ventricular effective refractory periods. After both oral and intravenous lorcainide, ventricular tachycardia could still be induced, but the arrhythmia was slower and better tolerated hemodynamically. The mean plasma lorcainide level during a maintenance intravenous infusion was 1254 + 662 ng/ml compared with a lorcainide level of 562 41 ng/ml and a norlorcainide level of 1212 + 653 ng/ml after oral dosing. No norlorcainide was detected in plasma after intravenous lorcainide. These data suggest that the shortterm electrophysiologic effects of intravenous lorcainide may be different from those of short-terrn therapy with the oral drug. These differences should be considered during short-term studies of lorcainide. Circulation 68, No. 2, 392-399, 1983. LORCAINIDE is a new antiarrhythmic drug that decreases the rate of rise of phase 0 of the cardiac intracellular action potential, and the conduction velocity, spontaneous activity, and effective refractory period in isolated dog Purkinje fibers, dog papillary muscles, and guinea pig auricles. I Lorcainide is clinically effective in the treatment of premature ventricular contractions, reciprocating supraventricular tachycardia using an accessory pathway, and ventricular tachycardia.2 -Previous studies have described the electrophysiologic effects of intravenous lorcainide in man, and several of these have included data on the effect of the drug on the inducibility of ventricular tachycardia.i-' In contrast to the large amount of data available describing the electrophysiologic effects of intravenous lorcainide, there are only limited data on the oral drug. During longterm oral therapy a metabolite, norlorcainide, accumulates to plasma concentrations approximately two
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In this study, we have compared the clinical electrophysiologic effects of lorcainide during short-term intravenous administration with those observed during short-term oral therapy in two similar groups of patients with recurrent ventricular tachycardia.
Methods
Patient selection. Twenty-one patients with recurrent sustained ventricular tachycardia that required drugs or cardioversion for termination took part in this study. 
Results
Comparability of groups A and B. There were no significant differences in the general clinical characteristics of patients in the two groups (table 1). The baseline electrophysiologic data for the groups were also analyzed for comparability. There was no statistical difference between groups in baseline QRS, QT, QTc, HV, or AH intervals or right atrial or ventricular effective refractory periods during paced rhythm. The characteristics of the induced ventricular tachycardias in the two groups before lorcainide differed in that the mean cycle length was longer (320 + 61 vs 256 ± 56 msec) and the mean blood pressure higher (66 ± 26 vs 40 + 14 mm Hg) in group A compared with in group B.
Drug dosing and plasma levels. Group A patients received a mean lorcainide loading dose of 146.7 ± 30.5 mg iv, and a mean maintenance infusion of 27.2 ± 7.4 mg iv. The plasma lorcainide level remained constant through the 40 min infusion, as depicted in figure 1. The mean plasma lorcainide concentration during the maintenance infusion was 1254 + 662 ng/ ml. No norlorcainide was present in any sample from group A. In group B the mean oral loading period before restudy was 8.2 ± 1.3 days. The median dose on the day of restudy was 200 mg bid, with a range of from 100 to 400 mg bid, and the mean lorcainide plasma concentration was 562 ± 411 ng/ml. The mean norlorcainide level was 1212 + 653 ng/ml. Electrophysiologic measurements. In group A, during the 20 min lorcainide loading infusion QRS, QT, and HV intervals were each progressively and significantly prolonged (figure 2). The spontaneous RR cycle length, AH interval, and mean arterial pressure did not change significantly.
The electrophysiologic values before and after lorcainide for each group, the mean percentage change, and statistical significance are summarized in table 2. In both groups the QRS, QT, QTc, and HV intervals were prolonged with lorcainide. However, the AH interval and the atrial and ventricular effective refractory periods were prolonged significantly (by 22.6%, 13.2%, and 17.3%, respectively) only after the oral loading dose (figure 3). In the majority of patients, the atrioventricular effective refractory period could not be determined because it was equal to or exceeded by the atrial effective refractory period. Ventricular tachycardia induction. In the baseline study sustained ventricular tachycardia could be induced in all patients in both groups and this effect was reproducible. One patient in group A had continuous ventricular tachycardia that was not terminated by an intravenous loading dose of lorcainide. After termination of the ventricular tachycardia with rapid pacing, tachycardia could not be reinduced. In all remaining patients in both groups, ventricular tachycardia remained inducible after lorcainide.
The ventricular tachycardia cycle length increased in nine of 10 patients after intravenous lorcainide infusion, and in 10 of 11 patients after oral lorcainide therapy ( Values, where appropriate, are mean ± SD. BP = blood pressure; SNRT = sinus node rhythm; WCL = Wenckebach cycle length; QTc -QT interval corrected for heart rate; A-ERP = right atrial effective refractory period during paced rhythm; V-ERP = right ventricular effective refractory period during paced rhythm; AVN-RRP = atrioventricular node relative refractory period; AVN-FRP = atrioventricular node functional refractory period.
Among individual patients the programmed stimulation mode required to induce ventricular tachycardia frequently changed slightly after lorcainide compared with baseline. However, there was no consistent trend toward making ventricular tachycardia either more difficult or easier to induce. Of note, however, was the observation that after lorcainide therapy ventricular tachycardia was induced by rapid atrial stimulation in five of the 21 patients. Tachycardia was not induced by this mode before lorcainide (figure 5). The ease of the effects of sodium channel-blocking drugs on sinus or atrioventricular nodal functions are not uncommon since these structures are heavily influenced by changes in autonomic tone. The studies of intravenous lorcainide do not demonstrate a consistent effect on the atrial effective refractory period. Although the study by Ng et al.7 showed a small but significant increase in the atrial effective refractory period at a dose of 2.5 mg/kg, there was no significant increase at a dose of 1.25 mg/kg or when data from the low and high doses were combined. The results of Kasper et al. 16 showed a significant increase in the ventricular effective refractory period, but the mean change was only 3.1%.
In our study, with administration of oral drug the QRS, QT, and HV intervals were prolonged to the same extent as after intravenous drug. However, in contrast to the findings after intravenous lorcainide, we also observed significant increases in the AH interval and in the atrial and ventricular effective refractory periods. The mean increases of 13.2% and 17.3% in atrial and ventricular effective refractory periods after oral drug were considerably greater than changes noted in any previous study (including the present one) after intravenous lorcainide. The different electrophysiologic effects of oral compared with intravenous drug was also recently reported for encainide.'2 The changes noted were similar to those in our study, with atrial and ventricular refractoriness prolonged only after oral encainide. It has been hypothesized that active encainide metabolites formed principally after oral dosing are responsible for the differing electrophysiologic effects. This may also be true for lorcainide. Norlorcainide plasma levels far exceeded lorcainide levels after several days of oral loading doses,' and perhaps the additional electrophysiologic effects reflect properties of norlorcainide in man. A discrepancy in electrophysiologic properties could cause variable responses to intravenous and oral preparations in a given patient. It is intriguing to speculate that the successful treatment with oral, but not intravenous, lorcainide of ventricular ectopy in two patients in another series4 was due to the differing electrophysiologic effects. However, in a canine study by Keefe et al.
I in which intravenous lorcainide and norlorcainide were administered as separate compounds no differences were found in electrophysiologic effects. Another possible explanation of the differences in electrophysiologic actions of oral and intravenous lorcainide could be a temporal alteration in lorcainide drug distribution and tissue saturation with a slower equilibration of drug effect on atrial and ventricular refractoriness compared with its other electrophysiologic effects. The mean lorcainide plasma level of 1254 ng/ml levels were observed in our patients after intravenous attained during maintenance infusion in our patients compared with after oral dosing eliminates the possireceiving intravenous drug is higher than the levels bility that the additional electrophysiologic effects of reported in patients in other series.4 16 The mean plasoral lorcainide were a dose-dependent phenomenon. ma lorcainide and norlorcainide concentrations of our In our study ventricular tachycardia could be inpatients receiving oral drug were also quite high comduced with programmed stimulation in all but one papared with those in other series,4
I a fact that in part tient after either oral or intravenous lorcainide therapy. reflects the higher drug doses used in these patients Breithardt et al.6 reported that ventricular tachycardia with refractory disease. The fact that higher lorcainide could be induced in eight of 11 patients after intrave- nous lorcainide loading, and in four of four patients on oral therapy. Bar et al.5 observed slowing of ventricular tachycardia rate followed by successful termination after intravenous lorcainide in four of five patients. The four patients successfully treated underwent programmed stimulation later and ventricular tachycardia could be induced again in three patients. In our study, the rates of the induced ventricular tachycardias were significantly slower, resulting in higher mean arterial pressures. The resultant hemodynamic stability during ventricular tachycardia has encouraged us to attempt long-term therapy in several patients with highly drugrefractory venticular tachycardia despite persistence of inducible ventricular tachycardia. The mode of stimulation required to induce ventricular tachycardia changed in many patients in our study, but there was no clear trend in terms of the number of ventricular extrastimuli needed for induction. These results are not exactly comparable to those of Bar et al. 5 and Breithardt et al.6 since they used less aggressive protocols in which only one extrastimulus or two extrastimuli were used. In Breithardt's study patients with plasma concentrations of lorcainide of greater than 660 ng/ml tended to require more aggressive stimulation for ventricular tachycardia induction, but in our study this correlation was not present. It is noteworthy that in five of our patients ventricular tachycardia was induced with rapid atrial pacing after lorcainide therapy. In our experience induction of ventricular tachycardia by this technique is quite uncommon at baseline so that the inducibility of tachycardia by this pacing mode after lorcainide seems to be a drug effect. Since we do not use this induction mode routinely after drug 398 administration (it was used in this study as a means of measurement of sinus node recovery time), we cannot compare this effect of lorcainide to that of other drugs studied in our laboratory.
We conclude that potentially important electrophysiologic differences may exist between orally and intravenously administered lorcainide. In virtually all patients ventricular tachycardia could still be induced after drug administration, but the rhythm was slower and better tolerated hemodynamically.
